Cover Image
Market Research Report
Product code
1008232

Biosimilars: Global Markets

Published: | BCC Research | 358 Pages | Delivery time: 1-2 business days

Price

Back to Top
Biosimilars: Global Markets
Published: May 21, 2021
BCC Research
Content info: 358 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Highlights:

The global biosimilars market should reach $60.1 billion by 2025 from $15.7 billion in 2020 at a compound annual growth rate (CAGR) of 30.9% for the forecast period of 2020 to 2025.

The monoclonal antibodies segment of biosimilars market is expected to grow from $7.0 billion in 2020 to $38.4 billion in 2025 at a CAGR of 40.5% for the forecast period of 2020 to 2025.

The recombinant growth factors segment of biosimilars market is expected to grow from $3.6 billion in 2020 to $9.4 billion in 2025 at a CAGR of 20.9% for the forecast period of 2020 to 2025.

Report Scope

Biosimilar drugs have gained immense popularity because of their impact on the lives of many patients. These drugs belong to several drug classes including hormones, interferons, growth factors (colony stimulating factors, erythropoietin) and monoclonal antibodies, among others. The use of these drugs has aided in the affordable treatment of many life-threatening diseases ranging from cancer and diabetes to chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and others. The high cost of branded biologics has made biosimilars a lucrative alternative for affordable treatment. According to a BCC Research report on biosimilars (BIO090C), the global market for biosimilars is expected to reach close to $20.8 billion by 2022, growing at a CAGR of 30.5%. Other drivers for this market include rising aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

This updated report for BCC Research provides in-depth analysis of the market for biosimilars in a global context, including market forecasts and sales through 2025. This study surveys the market for biosimilars in all the geographic regions including North America, Europe, the developed rest of the world (RoW), and emerging markets. The emerging markets include countries like India, China, Taiwan, Africa and Latin America.

The report provides an analysis of the market for biosimilars in various segments, for instance, by type, by region and by application/disease category. The report will include a detailed overview about the subject wherein the classification of biosimilar drugs along with their approval mechanisms, clinical trials and applications under review are elaborated upon.

The report also provides relevant patent analysis in both the U.S. and the European Union and comprehensive profiles of companies that lead the biosimilar drugs industry. The industry structure, focusing on the important biosimilar drug manufacturers/suppliers and their market shares and product offerings, is analyzed. This report also discusses the current market situation by elaborating upon the market drivers, restraints, challenges and opportunities. Separate chapters discuss the regulatory aspects and clinical trials. The latest news pieces including new products, new indications, mergers and acquisitions in the market are also dealt with in sufficient detail.

Excluded from this report are biobetters, generics of small molecule drugs and the biogenerics pertaining to vaccines and blood products. The different requirements for approval and bioequivalence between generics and biosimilars put them in an entirely different regime.

Report Includes

  • 69 data tables and 73 additional tables
  • An updated review and industry insights of the global biosimilars market
  • Analyses of the global market trends, with data from 2018 to 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Highlights of the emerging market regulations, clinical trials, and new products launches; and their impact on the stakeholders in this market
  • Discussion of the biosimilars industry structure, opportunities and complexities, regulatory updates and penetration of biosimilar product classes in various regions worldwide
  • Estimation of current market size and potential growth forecast for biosimilars market, and corresponding market share analysis by product type, application/disease category and geographic region
  • A detailed review of patents issued for biosimilars by different assignee categories
  • Impact analysis of COVID-19 pandemic on the growth of biosimilars market as compared to overall pharmaceuticals industry with respect to clinical trials/approvals
  • Company profiles of the major market players, including Amgen Inc., Boehringer Ingelheim, Cipla Ltd., Dr Reddy's Laboratories Ltd., Lupin Ltd., Pfizer Inc. and Zydus Cadila
Table of Contents
Product Code: BIO090D

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Terminology of Biosimilars
  • Definitions of Biosimilars
  • Development of a Biosimilar
  • Clone Development and Selection
  • Manufacture of a Biosimilar
  • Preclinical Studies and Validation of a Biosimilar
  • Clinical Trials
  • Approval by Regulatory Agencies
  • Pharmacovigilance/Post-Approval Monitoring
  • Biosimilars Versus Biobetters
  • Popular Types of Biosimilars
  • Recombinant Hormones
  • Recombinant Growth Factors
  • Monoclonal Antibodies (mAbs)
  • Fusion Proteins
  • Interferons
  • Low Molecular Weight Heparins (LMWHs)

Chapter 4 Market Breakdown by Type of Biosimilar

  • Global Market for Biosimilars by Type
  • Market Shares
  • Recombinant Hormone Biosimilars
  • Recombinant Growth Factor Biosimilars
  • Monoclonal Antibody Biosimilars
  • Fusion Protein Biosimilars
  • Interferons
  • LMWHs

Chapter 5 Market Breakdown by Therapeutic Application

  • Global Market for Therapeutic Applications of Biosimilars
  • Market Revenue
  • Cancer and Related Disorders
  • Diabetes
  • Anemia
  • Growth Hormone Deficiency
  • Autoimmune Diseases
  • Infectious Diseases
  • Other Types of Diseases

Chapter 6 Market Breakdown by Region

  • Introduction
  • Global Trends
  • Factors Impacting the Global Market for Biosimilars
  • Market by Geographical Region
  • North America
  • Europe
  • Developed Countries in the RoW Region
  • Emerging Markets
  • Recombinant Hormone Biosimilars
  • Market Revenue
  • Market Shares
  • Somatotropin Biosimilars
  • Follitropin Alfa Biosimilars
  • Insulin Biosimilars
  • Teriparatide Biosimilars
  • Recombinant Growth Factor Biosimilars
  • Market Revenue
  • Market Shares
  • Erythropoietin Biosimilars
  • Darbepoetin Alfa Biosimilars
  • Filgrastim Biosimilars
  • Pegfilgrastim Biosimilars
  • Monoclonal Antibody Biosimilars
  • Market Revenue
  • Market Shares
  • Adalimumab Biosimilars
  • Bevacizumab Biosimilars
  • Infliximab Biosimilars
  • Ranibizumab Biosimilars
  • Rituximab Biosimilars
  • Trastuzumab Biosimilars
  • Fusion Protein Biosimilars
  • Market Overview
  • Market Revenue
  • Market Shares
  • Interferon Biosimilars
  • Market Overview
  • Market Revenue
  • Market Shares
  • Low Molecular Weight Heparin (Enoxaparin Sodium) Biosimilars
  • Market Overview
  • Market Revenue
  • Market Shares

Chapter 7 Industry Structure

  • Types of Market Players
  • Established Biologics Companies
  • Established Generics Companies
  • Bio-intellectual Companies
  • Opportunistic Companies
  • Prioritizers
  • Emerging Trends in the Biosimilar Industry
  • Collaborations and Partnerships
  • Mergers and Acquisitions
  • Manufacturing Facilities of Major Market Players
  • Contract Manufacturing Organizations (CMOs)
  • Leading Manufacturers/Suppliers of Biosimilar Drugs
  • Recombinant Hormones
  • Recombinant Growth Factors
  • Monoclonal Antibodies
  • Fusion Proteins
  • Interferons
  • LMWHs

Chapter 8 Regulatory Aspects

  • Biosimilar Regulations in Europe
  • Impact of Brexit
  • Biosimilar Regulations in the U.S.
  • Principle of Exclusivity
  • Requirement of 351(k) Application
  • Approaches to Demonstrate Biosimilarity
  • Biosimilar Regulations in Emerging Markets
  • Biosimilar Guidelines in India
  • Biosimilar Regulations in China
  • Biosimilar Regulations in South Korea
  • Biosimilar Regulations in Japan
  • Biosimilar Regulations in Australia
  • Naming of Biosimilars
  • FDA Naming Convention
  • WHO Naming Convention
  • EMA Naming Convention
  • Interchangeability and Substitution

Chapter 9 Patent Analysis

  • Patent Regulations in Favor of Branded Biologics
  • Market Exclusivity
  • Patent Regulations in Favor of Biosimilars
  • Market Exclusivity
  • Product Versus Process Patents
  • Patent Activity in Biosimilars, 2018 Through February 2021
  • U.S. Patents
  • International Patents

Chapter 10 Clinical Trials

  • Biosimilars in Clinical Trials
  • Clinical Trials Analysis
  • Clinical Trials by Recruitment Status
  • Clinical Trials by Type of Study
  • Clinical Trials by Study Phase
  • Clinical Trials by Biosimilar Active Substance
  • Clinical Trials by Therapeutic Area
  • Biosimilar Candidates in Ongoing Clinical Trials

Chapter 11 Analysis of Market Forces

  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Opportunities
  • Issues

Chapter 12 Company Profiles

  • 3S BIO INC.
  • ALVOTECH
  • AMGEN INC.
  • BIOCAD
  • BIOCON LTD.
  • BIOEQ GMBH
  • BIOPARTNERS GMBH
  • BIOSIDUS S.A.
  • BIO-THERA SOLUTIONS LTD.
  • BIOXPRESS THERAPEUTICS S.A.
  • BLAU FARMACEUTICA S/A
  • BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
  • CHONG KUN DANG PHARMACEUTICAL CORP.
  • CELLTRION INC.
  • CIPLA LTD.
  • CINNAGEN
  • COHERUS BIOSCIENCES INC.
  • DM BIO LTD.
  • DONG-A SOCIO HOLDINGS
  • DR. REDDY'S LABORATORIES LTD.
  • EMCURE PHARMACEUTICALS LTD.
  • FRESENIUS KABI AG
  • FORMYCON AG
  • GEDEON RICHTER PLC
  • GENESCIENCE PHARMACEUTICALS CO., LTD.
  • GC PHARMA (FORMERLY GRESS CROSS CORP.)
  • HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD.
  • HANWHA CHEMICAL CORP.
  • HARVEST MOON PHARMACEUTICALS U.S.A. INC.
  • INNOVENT BIOLOGICS CO., LTD.
  • INTAS PHARMACEUTICALS LTD.
  • JHL BIOTECH INC.
  • JCR PHARMACEUTICALS CO., LTD.
  • KISSEI PHARMACEUTICAL CO., LTD.
  • LG CHEM (FORMERLY LG LIFE SCIENCES)
  • LUPIN LTD.
  • MABXIENCE S.A.
  • MYLAN N.V. (NOW VIATRIS INC.)
  • NANOGEN BIOPHARMACEUTICAL CO.
  • NEUCLONE
  • NIPPON KAYAKU CO., LTD.
  • PFENEX INC.
  • PFIZER INC.
  • PHARMAPARK LLC
  • PRESTIGE BIOPHARMA PTE LTD.
  • PROBIOMED S.A.
  • RELIANCE LIFE SCIENCES
  • SAMSUNG BIOEPIS CO., LTD.
  • SANDOZ INTERNATIONAL GMBH
  • SHANGHAI HENLIUS BIOTECH INC.
  • STADA ARZNEIMITTEL AG
  • TANVEX BIOPHARMA INC.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • USV PVT. LTD.
  • WOCKHARDT LTD.
  • XIAMEN AMOYTOP BIOTECH CO., LTD.
  • ZYDUS CADILA

Chapter 13 Appendix: Acronyms

List of Tables

  • Summary Table : Global Market for Biosimilars, by Type, Through 2025
  • Table 1 : Differences between Generic and Biosimilar Drugs
  • Table 2 : EMA Terminology Related to Biosimilars
  • Table 3 : FDA Terminology Related to Biosimilars
  • Table 4 : WHO Terminology Related to Biosimilars
  • Table 5 : Differences between E. coli and CHO Cell Lines
  • Table 6 : List of Biosimilars Produced in E. coli
  • Table 7 : Key Differences between Approval Pathways for Biosimilars in the EU and the U.S.
  • Table 8 : Biosimilars Versus Biobetters
  • Table 9 : Examples of Approved Biobetters
  • Table 10 : Representative Biobetters in Clinical Trials
  • Table 11 : Biosimilar Recombinant Hormones
  • Table 12 : Biosimilar Recombinant Growth Factors
  • Table 13 : Biosimilar Monoclonal Antibodies
  • Table 14 : Biosimilar Fusion Proteins
  • Table 15 : Biosimilar Interferons
  • Table 16 : Biosimilar LMWHs
  • Table 17 : Number of Approved Biosimilars, by Reference Product, February 2021
  • Table 18 : Global Market for Biosimilars, by Type, Through 2025
  • Table 19 : Global Market Share of Biosimilars, by Type, 2019
  • Table 20 : Global Market for Recombinant Hormone Biosimilars, by Type, Through 2025
  • Table 21 : Pegfilgrastim Biosimilars Approved, 2018-2020
  • Table 22 : Global Market for Recombinant Growth Factor Biosimilars, by Type, Through 2025
  • Table 23 : Branded Monoclonal Antibody Drugs Used as Reference Drugs for Biosimilars
  • Table 24 : FDA-approved Adalimumab Biosimilars
  • Table 25 : Trastuzumab Biosimilars
  • Table 26 : Global Market for Monoclonal Antibody Biosimilars, by Type, Through 2025
  • Table 27 : Global Market for Fusion Protein Biosimilars, by Type, Through 2025
  • Table 28 : Global Market for Interferon Biosimilars, by Type, Through 2025
  • Table 29 : Global Market for LMWH Biosimilars, Through 2025
  • Table 30 : Approved Biosimilars, by Therapeutic Application, March 2021
  • Table 31 : Global Market for Biosimilars, by Therapeutic Application, Through 2025
  • Table 32 : Global Market Share of Biosimilars, by Therapeutic Application, 2019
  • Table 33 : Global Market for Biosimilars in the Treatment of Cancer, by Region, Through 2025
  • Table 34 : Global Market for Biosimilars in the Treatment of Diabetes, by Region, Through 2025
  • Table 35 : Global Market for Biosimilars in the Treatment of Anemia, by Region, Through 2025
  • Table 36 : Global Market for Biosimilars in the Treatment of Growth Hormone Deficiency, by Region, Through 2025
  • Table 37 : Global Market for Biosimilars in the Treatment of Autoimmune Diseases, by Region, Through 2025
  • Table 38 : Global Market for Biosimilars in the Treatment of Infectious Diseases, by Region, Through 2025
  • Table 39 : Global Market for Biosimilars in the Treatment of Other Types of Diseases, by Region, Through 2025
  • Table 40 : Biosimilar Drug Approvals, by Country, 2005-2020
  • Table 41 : Global Market for Biosimilars, by Region, Through 2025
  • Table 42 : Global Market Share of Biosimilars, by Region, 2019
  • Table 43 : Global Market for Recombinant Hormone Biosimilars, by Region, Through 2025
  • Table 44 : Global Market Share of Recombinant Hormone Biosimilars, by Region, 2019
  • Table 45 : Global Market for Somatotropin Biosimilars, by Region, Through 2025
  • Table 46 : Global Market for Follitropin Alfa Biosimilars, by Region, Through 2025
  • Table 47 : Global Market for Insulin Biosimilars, by Region, Through 2025
  • Table 48 : Global Market for Teriparatide Biosimilars, by Region, Through 2025
  • Table 49 : Global Market for Recombinant Growth Factor Biosimilars, by Region, Through 2025
  • Table 50 : Global Market Share of Recombinant Growth Factor Biosimilars, by Region, 2019
  • Table 51 : Global Market for Erythropoietin Biosimilars, by Region, Through 2025
  • Table 52 : Global Market for Darbepoetin Alfa Biosimilars, by Region, Through 2025
  • Table 53 : Global Market for Filgrastim Biosimilars, by Region, Through 2025
  • Table 54 : Pegfilgrastim Pipeline
  • Table 55 : Global Market for Pegfilgrastim Biosimilars, by Region, Through 2025
  • Table 56 : Global Market for Monoclonal Antibody Biosimilars, by Region, Through 2025
  • Table 57 : Global Market Share of Monoclonal Antibody Biosimilars, by Region, 2019
  • Table 58 : Global Market for Adalimumab Biosimilars, by Region, Through 2025
  • Table 59 : Global Market for Bevacizumab Biosimilars, by Region, Through 2025
  • Table 60 : Global Market for Infliximab Biosimilars, by Region, Through 2025
  • Table 61 : Ranibizumab Biosimilars Pipeline
  • Table 62 : Global Market for Ranibizumab Biosimilars, by Region, Through 2025
  • Table 63 : Global Market for Rituximab Biosimilars, by Region, Through 2025
  • Table 64 : Global Market for Trastuzumab Biosimilars, by Region, Through 2025
  • Table 65 : Global Market for Fusion Protein Biosimilars, by Region, Through 2025
  • Table 66 : Global Market Share of Fusion Protein Biosimilars, by Region, 2019
  • Table 67 : Global Market for Interferon Biosimilars, by Region, Through 2025
  • Table 68 : Global Market Share of Interferon Biosimilars, by Region, 2019
  • Table 69 : Global Market for Low Molecular Weight Heparin (Enoxaparin Sodium) Biosimilars, by Region, Through 2025
  • Table 70 : Global Market Share of Low Molecular Weight Heparin (Enoxaparin Sodium) Biosimilars, by Region, 2019
  • Table 71 : Collaborations and Partnerships in the Market for Biosimilars, 2018-March 2021
  • Table 72 : Mergers and Acquisitions in the Market for Biosimilars, 2018-March 2021
  • Table 73 : Manufacturing Facilities of Major Companies in Biosimilars
  • Table 74 : Leading Manufacturers/Suppliers of Recombinant Hormone Biosimilars, 2019
  • Table 75 : Market Share of Leading Manufacturers/Suppliers of Recombinant Hormone Biosimilars, 2019
  • Table 76 : Leading Manufacturers/Suppliers of Recombinant Growth Factor Biosimilars, 2019
  • Table 77 : Market Share of Leading Manufacturers/Suppliers of Recombinant Growth Factor Biosimilars, 2019
  • Table 78 : Leading Manufacturers/Suppliers of Monoclonal Antibody Biosimilars, 2019
  • Table 79 : Market Share of Leading Manufacturers/Suppliers of Monoclonal Antibody Biosimilars, 2019
  • Table 80 : Leading Manufacturers/Suppliers of Fusion Protein Biosimilars, 2019
  • Table 81 : Market Share of Leading Manufacturers/Suppliers of Fusion Protein Biosimilars, 2019
  • Table 82 : Leading Manufacturers/Suppliers of interferons Biosimilars, 2019
  • Table 83 : Market Share of Leading Manufacturers/Suppliers of Interferons Biosimilars, 2019
  • Table 84 : Leading Manufacturers/Suppliers of LMWH Biosimilars, 2019
  • Table 85 : Market Share of Leading Manufacturers/Suppliers of LMWH Biosimilars, 2019
  • Table 86 : Product-specific Biosimilar Guidelines, EMA
  • Table 87 : Related Biosimilar Guidelines, EMA
  • Table 88 : Refused/Withdrawn Biosimilar Drugs, EMA
  • Table 89 : FDA Guidance on Biosimilars, February 2021
  • Table 90 : Biosimilar Products Approved in China
  • Table 91 : Biosimilar Products Approved in Korea, 2018-February 2021
  • Table 92 : Biosimilar Products Approved in Japan, 2018-February 2021
  • Table 93 : Biosimilar Products Approved in Australia, 2018-February 2021
  • Table 94 : FDA Recommendations for a Proposed Suffix in a Biosimilar Product Name
  • Table 95 : Approved Biosimilars with Proper and Proprietary Names
  • Table 96 : U.S. Patent Expirations and Biosimilars
  • Table 97 : Pending Biosimilar Patent Litigation
  • Table 98 : Inter Partes Review (IPR) Challenges by Biosimilar Developers, 2018-February 2021
  • Table 99 : Patent Litigation in Favor of Biosimilar Manufacturers
  • Table 100 : Patents Issued on Biosimilars, by Year, 2018-February 2021
  • Table 101 : Patents Issued on Biosimilars, by Type, 2018-February 2021
  • Table 102 : Patents Issued on Biosimilars, by Company, 2018-February 2021
  • Table 103 : Patents Issued on Biosimilars, by Assignee's Country, 2018-February 2021
  • Table 104 : Patents Issued on Biosimilars, by Type of Assignee, 2018-February 2021
  • Table 105 : WIPO Patents Issued on Biosimilars, by Year, 2018-February 2021
  • Table 106 : WIPO Patents Issued on Biosimilars, by Type, 2018-February 2021
  • Table 107 : WIPO Patents Issued on Biosimilars, by Company, 2018-February 2021
  • Table 108 : WIPO Patents Issued on Biosimilars, by Country/Patent Office Where Filed, 2018-February 2021
  • Table 109 : Major Biosimilar Candidates with Patent Expirations
  • Table 110 : Clinical Trials on Biosimilars, by Recruitment Status, 2018-February 2020
  • Table 111 : Clinical Trials on Biosimilars, by Type of Study
  • Table 112 : Clinical Trials on Biosimilars, by Study Phase
  • Table 113 : Clinical Trials on Biosimilars, by Biosimilar Active Substance
  • Table 114 : Clinical Trials on Biosimilars, by Therapeutic Area
  • Table 115 : Ongoing Clinical Trials on Biosimilar Candidates
  • Table 116 : Biosimilars in Clinical Trials, by Sponsor
  • Table 117 : Discounts and Prices of Biosimilar Drugs at Launch
  • Table 118 : 3S Bio's Biosimilar Pipeline
  • Table 119 : Alvotech's Biosimilar Partnerships
  • Table 120 : Amgen's Biosimilar Pipeline
  • Table 121 : Biocad's Biosimilar Pipeline
  • Table 122 : Biocon's Biosimilars
  • Table 123 : Bioeq's Biosimilar Pipeline
  • Table 124 : Bio-Thera Solutions' Biosimilar Pipeline
  • Table 125 : BioXpress Therapeutics' Biosimilar Development Programs
  • Table 126 : CKD Pharmaceuticals' Biosimilar Development Programs
  • Table 127 : Celltrion's Biosimilar Development Programs
  • Table 128 : Coherus Biosciences' Biosimilar Development Programs
  • Table 129 : DM Bio's Biosimilar Development Programs
  • Table 130 : Dong A-ST's Biosimilar Development Programs
  • Table 131 : Dr Reddy's Laboratories' Biosimilar Development Programs
  • Table 132 : Fresenius Kabi's Biosimilar Development Programs
  • Table 133 : Formycon's Biosimilar Development Programs
  • Table 134 : Gedeon Richter's Biosimilar Development Programs
  • Table 135 : Lupin's Biosimilar Development Programs
  • Table 136 : Mylan's Biosimilar Development Programs
  • Table 137 : Samsung Bioepis' Biosimilar Development Programs
  • Table 138 : Henlius Biotech's Biosimilar Development Programs
  • Table 139 : Tanvex Biopharma's Biosimilar Development Programs
  • Table 140 : Teva Pharmaceuticals' Biosimilar Development Programs
  • Table 141 : Acronyms Used in the Market for Biosimilars

List of Figures

  • Summary Figure : Global Market for Biosimilars, by Type, 2018-2025
  • Figure 1 : Depiction of a Typical Biosimilar Drug Development Timeline
  • Figure 2 : Global Market for Biosimilars, by Type, 2018-2025
  • Figure 3 : Global Market Share of Biosimilars, by Type, 2019
  • Figure 4 : Global Market for Recombinant Hormone Biosimilars, by Type, 2018-2025
  • Figure 5 : Global Market for Recombinant Growth Factor Biosimilars, by Type, 2018-2025
  • Figure 6 : Global Market for Monoclonal Antibody Biosimilars, by Type, 2018-2025
  • Figure 7 : Global Market for Fusion Protein Biosimilars, by Type, 2018-2025
  • Figure 8 : Global Market for Interferon Biosimilars, by Type, 2018-2025
  • Figure 9 : Global Market for LMWH Biosimilars, by Type, 2018-2025
  • Figure 10 : Global Market for Biosimilars, by Therapeutic Application, 2018-2025
  • Figure 11 : Global Market Share of Biosimilars, by Therapeutic Application, 2019
  • Figure 12 : Global Market for Biosimilars in the Treatment of Cancer, by Region, 2018-2025
  • Figure 13 : Global Market for Biosimilars in the Treatment of Diabetes, by Region, 2018-2025
  • Figure 14 : Global Market for Biosimilars in the Treatment of Anemia, by Region, 2018-2025
  • Figure 15 : Global Market for Biosimilars in the Treatment of Growth Hormone Deficiency, by Region, 2018-2025
  • Figure 16 : Global Market for Biosimilars in the Treatment of Autoimmune Diseases, by Region, 2018-2025
  • Figure 17 : Global Market for Biosimilars in the Treatment of Infectious Diseases, by Region, 2018-2025
  • Figure 18 : Global Market for Biosimilars in the Treatment of Other Types of Diseases, by Region, 2018-2025
  • Figure 19 : Global Market for Biosimilars, by Region, 2018-2025
  • Figure 20 : Global Market Share of Biosimilars, by Region, 2019
  • Figure 21 : Global Market for Recombinant Hormone Biosimilars, by Region, 2018-2025
  • Figure 22 : Global Market Share of Recombinant Hormone Biosimilars, by Region, 2019
  • Figure 23 : Global Market for Somatotropin Biosimilars, by Region, 2018-2025
  • Figure 24 : Global Market for Follitropin Alfa Biosimilars, by Region, 2018-2025
  • Figure 25 : Global Market for Insulin Biosimilars, by Region, 2018-2025
  • Figure 26 : Global Market for Teriparatide Biosimilars, by Region, 2018-2025
  • Figure 27 : Global Market for Recombinant Growth Factor Biosimilars, by Region, 2018-2025
  • Figure 28 : Global Market Share of Recombinant Growth Factor Biosimilars, by Region, 2019
  • Figure 29 : Global Market for Erythropoietin Biosimilars, by Region, 2018-2025
  • Figure 30 : Global Market for Darbepoetin Alfa Biosimilars, by Region, 2018-2025
  • Figure 31 : Global Market for Filgrastim Biosimilars, by Region, 2018-2025
  • Figure 32 : Global Market for Pegfilgrastim Biosimilars, by Region, 2018-2025
  • Figure 33 : Global Market for Monoclonal Antibody Biosimilars, by Region, 2018-2025
  • Figure 34 : Global Market Share of Monoclonal Antibody Biosimilars, by Region, 2019
  • Figure 35 : Global Market for Adalimumab Biosimilars, by Region, 2018-2025
  • Figure 36 : Global Market for Bevacizumab Biosimilars, by Region, 2018-2025
  • Figure 37 : Global Market for Infliximab Biosimilars, by Region, 2018-2025
  • Figure 38 : Global Market for Ranibizumab Biosimilars, by Region, 2018-2025
  • Figure 39 : Global Market for Rituximab Biosimilars, by Region, 2018-2025
  • Figure 40 : Global Market for Trastuzumab Biosimilars, by Region, 2018-2025
  • Figure 41 : Global Market for Fusion Protein Biosimilars, by Region, 2018-2025
  • Figure 42 : Global Market Share of Fusion Protein Biosimilars, by Region, 2019
  • Figure 43 : Global Market for Interferon Biosimilars, by Region, 2018-2025
  • Figure 44 : Global Market Share of Interferon Biosimilars, by Region, 2019
  • Figure 45 : Global Market for Low Molecular Weight Heparin (Enoxaparin Sodium) Biosimilars, by Region, 2018-2025
  • Figure 46 : Global Market Share of Low Molecular Weight Heparin (Enoxaparin Sodium) Biosimilars, by Region, 2019
  • Figure 47 : Market Share of Leading Manufacturers/Suppliers of Recombinant Hormone Biosimilars, 2019
  • Figure 48 : Market Share of Leading Manufacturers/Suppliers of Recombinant Growth Factor Biosimilars, 2019
  • Figure 49 : Market Share of Leading Manufacturers/Suppliers of Monoclonal Antibody Biosimilars, 2019
  • Figure 50 : Market Share of Leading Manufacturers/Suppliers of Fusion Protein Biosimilars, 2019
  • Figure 51 : Market Share of Leading Manufacturers/Suppliers of Interferon Biosimilars, 2019
  • Figure 52 : Market Share of Leading Manufacturers/Suppliers of LMWH Biosimilars, 2019
  • Figure 53 : Patents Issued on Biosimilars, by Year, 2018-February 2021
  • Figure 54 : Patents Issued on Biosimilars, by Assignee's Country, 2018-February 2021
  • Figure 55 : Patents Issued on Biosimilars, by Type of Assignee, 2018-February 2021
  • Figure 56 : WIPO Patents Share Issued on Biosimilars, by Year, 2018-February 2021
  • Figure 57 : WIPO Patents Issued on Biosimilars, by Type, 2018-February 2021
  • Figure 58 : WIPO Patents Issued on Biosimilars, by Country/Patent Office Where Filed, 2018-February 2021
  • Figure 59 : Clinical Trials on Biosimilars, by Recruitment Status, 2018-February 2020
  • Figure 60 : Clinical Trials on Biosimilars, by Type of Study
  • Figure 61 : Clinical Trials on Biosimilars, by Study Phase
  • Figure 62 : Clinical Trials on Biosimilars, by Active Substance
  • Figure 63 : Clinical Trials on Biosimilars, by Therapeutic Area
  • Figure 64 : SWOT Analysis of the Market for Biosimilars
  • Figure 65 : Biosimilar Discounts at Product Launch